NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

Rhea-AI Summary

NeuBase Therapeutics (NASDAQ: NBSE) announced that CEO Dietrich A. Stephan, Ph.D., will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The on-demand presentation will be available starting January 11 at 6:00 a.m. ET and can be accessed on NeuBase's website. NeuBase is focused on accelerating the genetic revolution with its synthetic medicines aimed at treating genetic diseases through its proprietary PATrOL™ therapies, targeting neurological, neuromuscular, and oncologic disorders.

PITTSBURGH, Jan. 11, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview during the H.C. Wainwright Virtual BioConnect Conference, which is being held from January 11 - 14, 2021. A webcast of the on-demand presentation will be available beginning today at 6:00 a.m. Eastern Time and archived on the NeuBase website, www.neubasetherapeutics.com.  

About NeuBase Therapeutics
NeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase’s designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.

NeuBase Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
OP: (617) 430-7576

NeuBase Media Contact:
Cait Williamson, Ph.D.
LifeSci Public Relations
cait@lifescipublicrelations.com
OP: (646) 751-4366

FAQ

When will NeuBase present its corporate overview?

NeuBase will present its corporate overview during the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021.

Where can I watch the NeuBase presentation?

The NeuBase presentation will be available on-demand starting January 11 at 6:00 a.m. ET on NeuBase's website.

What is NeuBase's focus in biotechnology?

NeuBase focuses on accelerating the genetic revolution with synthetic medicines to treat genetic diseases, primarily through its PATrOL™ therapies.

What types of disorders does NeuBase aim to address?

NeuBase aims to address neurological, neuromuscular, and oncologic disorders with its targeted therapies.

What is the stock symbol for NeuBase?

The stock symbol for NeuBase is NBSE.